Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Avoids Pradaxa Trial, Board Chair Deposition With $650 Mil. Settlement

This article was originally published in The Pink Sheet Daily

Executive Summary

Settlement expected to resolve approximately 4,000 Pradaxa personal injury claims.

Advertisement

Related Content

Strong Xarelto Label Warnings Lead To Another Jury Win For Bayer And Janssen
Xarelto Liability Suit: Is Label 'Silent' About Increased Bleeding Risk?
Can Praxbind Push Pradaxa Ahead?
Pradaxa Bleeding Events Prompt FDA To Revise Generic Bioequivalence Criteria
Boehringer Files Pradaxa Antidote, Could Lead To Reversible Novel Anticoagulant
Boehringer Files Pradaxa Antidote, Could Be First Reversible Novel Anticoagulant
Product Liability Suits: Testosterone, Lipitor Grow While Yaz, Pradaxa Settle
Pradaxa Bleeding Risk Gets Deeper FDA Scrutiny In Mini-Sentinel Project
Mini Sentinel Alleviates FDA Concern Over Pradaxa Bleeding Issue
Pradaxa Bleeding Deaths Spur FDA Concerns, European Label Changes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077260

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel